Previous 10 | Next 10 |
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q2 earnings Read more ...
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® – – First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 – – Work restrictions at the NCI and MD Anderso...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 202...
– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech – – Managing Partner at Kleiner Perkins Caufield & Byers China; Founder of Panace...
The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...
Are These On Your List Of Penny Stocks To Watch? What can be considered a catalyst? For most penny stocks , any big company event tends to bring a reaction from the market. Whether that reaction is positive or negative is secondary. The main thing you should understand as a trader is that pe...
Ziopharm Oncology (NASDAQ: ZIOP ) initiates a 24-subject Phase 1 clinical trial evaluating CD19-specific CAR-T cells in patients with relapsed CD19-positive leukemias and lymphomas. More news on: ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technol...
BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veled...
MyoKardia Reports Upbeat Phase 2a Clinical Data MyoKardia Inc. ( MYOK ) announced that its Phase 2a clinical trial of danicamtiv has yielded positive results. The company also discussed nonclinical data showing the novel mechanism of action of the drug candidate. Danicamtiv is MyoKar...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...